Cresilon
cresilon.com
Actively hiring
Oncology Therapeutics
Medical Supplies & Consumables
As featured in
View 5 jobs
Claim pageClaim
Follow
Overview
Connections
News
Technologies
Salaries
Products
People
Growth
Offices
Jobs
Financials
Funding and backers
Total raised
$167.4M
9 rounds on record
Latest round
$6.7M
Venture round · Nov 2025 · 11 mo ago
Team
60
US Form 5500 (plan participants) · Dec 2024
Hiring now
6
open roles
Backers
1
Dorm Room Fund
The money's age
Fresh money
11 months since the last round · hiring slowed
Momentum
30/100
a new city, fresh money
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Apr 24
Took on debt financing $29M · SEC Form D
Nov 21, 2025
Raised a round Venture round $6.7M · SEC Form D
Apr 11, 2025
Raised a round Venture round $17.2M · SEC Form D
Aug 19, 2024
Certified Cresilon Receives FDA Clearance for TRAUMAGEL · manilatimes.net
Apr 18, 2024
Raised a round Venture round $25M · SEC Form D
Aug 3, 2023
Raised a round Venture round $17.2M · SEC Form D
Jun 28, 2023
Certified Cresilon Receives First FDA Clearance For Human Use of Hemostatic Gel Technology · medindia.net
Dec 17, 2021
Raised a round Venture round $25M · SEC Form D
Apr 8, 2021
Raised a round Series A $38.5M · troyrecord
Dec 29, 2017
Raised a round Venture round $13.3M · SEC Form D
Sep 2016
Website went live first capture in the Wayback Machine
Tractionpublic signals, read monthly
Web presence
top 2%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Debt Financing | Apr 2026 | $29M | — | SEC Form D |
| Venture round | Nov 2025 | $6.7M | — | SEC Form D |
| Venture round | Apr 2025 | $17.2M | — | SEC Form D |
| Venture round | Apr 2024 | $25M | — | SEC Form D |
| Venture round | Aug 2023 | $17.2M | — | SEC Form D |
| Venture round | Dec 2021 | $25M | — | SEC Form D |
| Series A | Apr 2021 | $38.5M | — | troyrecord |
| Venture round | Jan 2021 | $24.5M | — | SEC Form D |
| Venture round | Dec 2017 | $13.3M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Cresilon, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Isaac MillerDirectorSEC Form D
Joseph LandolinaExecutive Officer, DirectorSEC Form D
Scott LevineExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
backs Cayuga Biotech
backs Tassoinc
Similar startupsby what they do, their industry and backers
Answers to all your questions in seconds. Snap a photo, get solutions instantly with Answers AI.
Find, price, and book nationwide reefer LTL freight in seconds with FreshX: The platform that connects you to top carriers with fast…
Cayuga Biotech is developing novel therapies to address life-threatening hemorrhage byharnessing the body’s innate ability to stop bleeding.
Better blood collection is here. Unlock a proven patient experience without painful needles or finger sticks.
AmorSui is building the next generation of PPE for healthcare professionals and scientists. Our designs set a new standard for PPE that is…
Behind the Seams Wicked Sheetsbegan with a simple idea: to address founderAlli Truttmann’sproblem ofnight sweatsthat left her waking with a…
Visa sponsorship
0
H-1B filings in 12 months
6
Open roles in United States
In the register as Cresilon Inc., Brooklyn, NY
Other sponsors in the same field
Eli Lilly and Company 420 filings
Regeneron Pharmaceuticals 316 filings
AbbVie 236 filings
Genentech 188 filings
See 6 open roles Alert me
US Department of Labor · latest filing May 19, 2025 · Visa details by country
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Dorm Room FundVia a fund
196 portfolio companies: Perennial Climate Inc., Pashionfootwear, 2026 Habitual Money Inc. and 193 more
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Cresilon Announces U.S. Nationwide Launch of TRAUMAGEL
/PRNewswire/ -- Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, announced the U.S....
Read more
Report
Cresilon's $25M Fundraise Could Help its Hemostatic Gel Hit the Human Health Market
Cresilon, a startup that makes a hemostatic gel to stop bleeding, has raised $25 million in a Series A-4 financing round. The round brings the company's total funding to date to nearly $82 million. The funds will help support Cresilon's entrance into the
Read more
Report
Cresilon Closes $38.5 Million Series A-3 Financing to Accelerate Commercialization of Hemostatic Gel
NEW YORK, April 8, 2021 /PRNewswire/ - Cresilon, Inc., the Brooklyn-based biotechnology company, announced today the successful close of its Series A-3 financing, totaling $38.5 million. This financing is expected to allow the company to aggressively acce
Read more
Report
Tech stack
Technologies named in job postings at Cresilon over the last 12 months, by layer, with the share of postings for each.
Technologies in use
15
Postings analysed
5
Stack modernity
61/100
Languages
Python
SQL
Sign in to see how your skills match this stack
Sign In
Full Cresilon tech stack
15 technologies · by team · pay by technology · changes · similar stacks
Salary insights
Compensation ranges based on this company's open jobs
Median
$110k
Typical range
$48k – $210k
Open positions
6
5
Jobs
Intern
20%
Junior
20%
Senior
20%
Principal
40%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Intern | 1 | $60k | $60k |
| Junior | 1 | $48k | $48k |
| Senior | 1 | $160k | $160k |
| Principal | 2 | $195k | $180k – $210k |
Highest paying role
Preclinical Principal Scientist, Research & Development
$210k
Normalized to USD per year
All salaries at Cresilon
By role, level and city, against the market · 6 jobs with pay
People
Isaac Miller
Director
Joseph Landolina
Executive Officer, Director
Scott Levine
Executive Officer
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Growth
Hiring Momentum
63/100
Growing
Open positions
6
0 opened / 0 closed in 30 days
ATS activity
Every ~8 hours
Today
Hiring Dynamics
+100%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Science & Research
50% ▼
Industrial Engineering
25% ▼
Early Careers
25% ▲
Activity Timeline
New location: Brooklyn
Sep 2026
Added SQL to stack
Sep 2026
Added Python to stack
Sep 2026
Added Microsoft Office to stack
Sep 2026
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
1
Countries
1
Busiest office
Brooklyn
Brooklyn
United States
HQ
Brooklyn
United States
Plant / site
6 open roles 4 posted in 90 days 33% engineering $118k Avg Salary
hires for Science & Research, Field & Service, Industrial Engineering
Jobs
$60k per year · In office · Internship · Brooklyn
Python
SQL
ISO 13485
21 CFR Part 820
Verification & Validation
Apply
$100k – $160k per year · In office · Full-Time · Bachelor's Degree · Brooklyn
Microsoft Excel
Design
SolidWorks
Life Sciences
GMP
GLP
MedTech
ISO 13485
ISO 14971
21 CFR Part 820
Design Controls
Design History File
Verification & Validation
Apply
$130k – $210k per year · Hybrid · Full-Time · PhD · Brooklyn
GMP
GLP
MedTech
ISO 13485
21 CFR Part 820
EU MDR
Design Controls
ISO 10993
Apply
$130k – $180k per year · In office · Full-Time · PhD · Brooklyn
GMP
MedTech
ISO 13485
21 CFR Part 820
FDA 510(k)
Design Controls
Apply
$40k – $48k per year · In office · Full-Time · Brooklyn
GMP
Apply
Financials
Total raised
$196.4M
Latest round
Debt Financing
Funding rounds
9
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Debt Financing | 2026 | $29M | Details |
| Venture - Series Unknown | 2025 | $6.7M | Details |
| Venture - Series Unknown | 2025 | $17.2M | Details |
| Venture - Series Unknown | 2024 | $25M | Details |
| Venture - Series Unknown | 2023 | $17.2M | Details |
| Venture - Series Unknown | 2021 | $25M | Details |
| Series A | 2021 | $38.5M | Details |
| Venture - Series Unknown | 2021 | $24.5M | Details |
| Venture - Series Unknown | 2017 | $13.3M | Details |